Skip to main content
. 2017 Aug 6;8(40):66925–66939. doi: 10.18632/oncotarget.19963

Figure 11. Ov-Mito-Signature 2 predicts the response to therapy in ovarian cancer patients.

Figure 11

Note that high levels of Ov-Mito-Signature 2 (NDUFA3/UQCRFS1) effectively predicts drug-resistance and treatment failure, illustrated here as overall survival. Results with Platin and Taxol therapy (Rx) are shown.